Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8824306 | 0.89 | HRH3 (0.46) | HRH3KDM4ECYP2D6MAPTLMNA | |
| SCHEMBL471858 | 0.87 | KDM4E (0.60) | HRH3KDM4ECYP2D6MAPTLMNA | |
| SCHEMBL9150008 | 0.85 | HRH3 (0.46) | HRH3KDM4ECYP2D6MAPTLMNA | |
| SCHEMBL8824282 | 0.84 | HRH3 (0.43) | HRH3KDM4ECYP2D6MAPTLMNA | |
| SCHEMBL8824308 | 0.84 | HRH3 (0.43) | HRH3KDM4ECYP2D6MAPTLMNA | |
| SCHEMBL10768863 | 0.83 | KDM4E (0.45) | HRH3KDM4ECYP2D6MAPTLMNA | |
| SCHEMBL3030444 | 0.81 | HRH3 (0.50) | HRH3KDM4ECYP2D6MAPTLMNA | |
| SCHEMBL1996001 | 0.81 | KDM4E (0.51) | HRH3KDM4EMAPTLMNAHTT | |
| SCHEMBL20409590 | 0.80 | KDM4E (0.53) | HRH3KDM4ECYP2D6MAPTLMNA | |
| SCHEMBL3942245 | 0.80 | KDM4E (0.53) | HRH3KDM4ECYP2D6MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115724706-B | Method for rapidly converting aldehyde group into cyano group | 中国科学院兰州化学物理研究所 | 2024-04-12 | — | — | CN | disclosed |
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| CN-115724706-A | Method for quickly converting aldehyde group into cyano group | 中国科学院兰州化学物理研究所 | 2023-03-03 | — | — | CN | disclosed |
| CN-115667225-A | Compound (I) | 詹森药业有限公司 | 2023-01-31 | — | — | CN | disclosed |
| WO-2021239885-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-02 | — | — | WO | disclosed |
| US-7879846-B2 | e.g. 2-(2-Imidazol-1-yl-pyridin-3-yl)-5-methyl-4H-benz[d][1,3]oxazin-4-one ; neutrophil elastase inhibitor; antiinflammatory agent, respiratory system disorders | Kyorin Pharmaceutical Co.., Ltd. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-7879846-B2 | e.g. 2-(2-Imidazol-1-yl-pyridin-3-yl)-5-methyl-4H-benz[d][1,3]oxazin-4-one ; neutrophil elastase inhibitor; antiinflammatory agent, respiratory system disorders | Kyorin Pharmaceutical Co.., Ltd. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20080161290-A1 | Serine hydrolase inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| US-20080161290-A1 | Serine hydrolase inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| US-6388077-B1 | CARDIOVASCULAR DISORDERS; CENTRAL NERVOUS SYSTEM DISORDERS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-05-14 | — | — | US | disclosed |
| US-20020052371-A1 | NOVEL SPIRO COMPOUNDS | MSD K.K. (JP) | 2002-05-02 | — | — | US | disclosed |
| US-6335345-B1 | NEUROPEPTIDE Y RECEPTOR ANTAGONISTS; OBESITY AND BULIMIA TREATMENT; CENTRAL NERVOUS SYSTEM, PSYCHOLOGICAL, METABOLIC AND EATING DISORDERS; ANTIDIABETIC AGENTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-01-01 | — | — | US | disclosed |
| US-6329370-B1 | CARDIOVASCULAR DISORDERS AND TUMOR NECROSIS FACTOR (HEREINAFTER TNF.SUB..ALPHA.), A CYTOKINE WITH PRO-INFLAMMATORY ACTIVITY | ZAMBON GROUP S.P.A. (IT) | 2001-12-11 | — | — | US | disclosed |
| US-6326375-B1 | CONTAINING AN UREA GROUP | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2001-12-04 | — | — | US | disclosed |
| EP-1097142-A1 | PHTHALAZINE DERIVATIVES PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON GROUP S.p.A. (IT) | 2001-05-09 | — | — | EP | disclosed |
| WO-2000005218-A1 | PHTHALAZINE DERIVATIVES PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON GROUP S.P.A. (IT) | 2000-02-03 | — | — | WO | disclosed |
| WO-1998038168-A1 | ISOQUINOLINONE DERIVATIVES, PROCESS FOR PREPARING THE SAME, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | TANABE SEIYAKU CO., LTD. (JP) | 1998-09-03 | — | — | WO | disclosed |
| EP-0365149-A2 | Leukotriene antagonist prodrugs | SMITHKLINE BEECHAM CORPORATION (US) | 1990-04-25 | — | — | EP | disclosed |
| US-3953432-A | OXAZOLINE DERIVATIVES | COMMERCIAL SOLVENTS CORPORATION (US) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202989-A1 | COMPOUNDS | NLRP3, NLRP1, IL1B | HRH3 930/4885KDM4E 3777/4885CYP2D6 1827/4885 |
| US-20020052371-A1 | NOVEL SPIRO COMPOUNDS | GPR119, NPY1R, OPRK1 | HRH3 360/4885KDM4E 3112/4885CYP2D6 930/4885 |
| US-20080161290-A1 | Serine hydrolase inhibitors | SERPINB1, ELANE, EPX | HRH3 598/4885KDM4E 1816/4885CYP2D6 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.